- Home
- DM vs TLSI Comparison
DM vs TLSI Comparison
Compare DM & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DM
- TLSI
- Stock Information
- Founded
- DM 2015
- TLSI 2010
- Country
- DM United States
- TLSI United States
- Employees
- DM N/A
- TLSI N/A
- Industry
- DM Industrial Machinery/Components
- TLSI Medical Specialities
- Sector
- DM Technology
- TLSI Health Care
- Exchange
- DM Nasdaq
- TLSI Nasdaq
- Market Cap
- DM 153.0M
- TLSI 124.9M
- IPO Year
- DM N/A
- TLSI N/A
- Fundamental
- Price
- DM $4.41
- TLSI $4.43
- Analyst Decision
- DM Hold
- TLSI Strong Buy
- Analyst Count
- DM 1
- TLSI 5
- Target Price
- DM $5.50
- TLSI $12.10
- AVG Volume (30 Days)
- DM 290.7K
- TLSI 30.3K
- Earning Date
- DM 10-31-2024
- TLSI 11-14-2024
- Dividend Yield
- DM N/A
- TLSI N/A
- EPS Growth
- DM N/A
- TLSI N/A
- EPS
- DM N/A
- TLSI N/A
- Revenue
- DM $168,283,000.00
- TLSI $26,892,000.00
- Revenue This Year
- DM $1.01
- TLSI $61.76
- Revenue Next Year
- DM N/A
- TLSI $47.30
- P/E Ratio
- DM N/A
- TLSI N/A
- Revenue Growth
- DM N/A
- TLSI 67.92
- 52 Week Low
- DM $3.62
- TLSI $3.33
- 52 Week High
- DM $11.80
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- DM 45.16
- TLSI 56.00
- Support Level
- DM $4.10
- TLSI $3.74
- Resistance Level
- DM $4.60
- TLSI $4.66
- Average True Range (ATR)
- DM 0.23
- TLSI 0.36
- MACD
- DM -0.03
- TLSI 0.02
- Stochastic Oscillator
- DM 53.54
- TLSI 78.47
About DM Desktop Metal Inc.
Desktop Metal Inc manufactures 3D printing to make metal and carbon fiber 3D printing accessible to all engineers, designers, and manufacturers. 3D metal printing helps in the design and development of automotive parts, consumer goods, manufacture of industrial equipment, and design of mechanical systems. The company ships its product to markets in the Americas, Europe Middle East and Africa (EMEA), and Asia Pacific (APAC). It derives maximum revenue from Americas.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.